Advertisement
Advertisement
U.S. Markets close in 4 hrs 40 mins
Advertisement
Advertisement
Advertisement
Advertisement

Artelo Biosciences, Inc. (ARTL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3198+0.0175 (+5.79%)
As of 11:17AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3023
Open0.3109
Bid0.3125 x 800
Ask0.3199 x 1000
Day's Range0.3102 - 0.3200
52 Week Range0.2810 - 1.3200
Volume131,271
Avg. Volume1,405,270
Market Cap13.528M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3980
Earnings DateJan 12, 2022 - Jan 17, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.08
  • GlobeNewswire

    Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

    Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26thSOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Bios

  • GlobeNewswire

    Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland

    SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Artelo’s Vice President of Translational Sciences, has been selected for an oral presentation at the 32nd International Cannabinoid Research Society (ICRS) Symposium, on Sunday, June

  • GlobeNewswire

    Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th

    SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the LD Micro conference which is being held on June 7– 9, 2022, at the Four Seasons Westlake Village, California. Mr. Gorgas is scheduled

Advertisement
Advertisement